-$0.56 in expected earnings per share for DICE Therapeutics, Inc. (NASDAQ:DICE) this quarter

Brokers expect DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) to report earnings per share of ($0.56) for the current fiscal quarter, reports Zacks Investment Research. Zero analysts provided earnings estimates for DICE Therapeutics. The company is due to release its next quarterly results on Monday, January 1.

On average, analysts expect DICE Therapeutics to report full year earnings of ($2.33) per share for the current year, with EPS estimates ranging from ($2.33) to ($2.33) per share. $.32). For the next fiscal year, analysts expect the company to post earnings of ($3.38) per share, with EPS estimates ranging from ($3.58) to ($3.18). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts who cover DICE Therapeutics.

DICE Therapeutics (NASDAQ:DICE – Get Rating) last released its quarterly results on Thursday, May 12. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04.

Separately, Zacks Investment Research upgraded DICE Therapeutics from a “sell” rating to a “hold” rating in a Monday, May 23 research report.

DICE opened at $14.69 on Friday. DICE Therapeutics has a 12 month minimum of $13.22 and a 12 month maximum of $40.50. The company has a debt ratio of 0.01, a current ratio of 20.75 and a quick ratio of 20.75. The company’s fifty-day simple moving average is $17.91 and its 200-day simple moving average is $19.73.

Major investors have recently changed their stake in the company. Virtus ETF Advisers LLC acquired a new stake in DICE Therapeutics in the fourth quarter valued at $169,000. Strs Ohio acquired a new stake in DICE Therapeutics in Q4, valued at approximately $80,000. RA Capital Management LP acquired a new stake in DICE Therapeutics in Q3 valued at approximately $170,592,000. Deep Track Capital LP bought a new stock position in DICE Therapeutics in Q4 valued at approximately $33,941,000. Finally, Janus Henderson Group PLC bought a new position in shares of DICE Therapeutics in Q3 valued at approximately $58,627,000. 82.91% of the shares are currently held by hedge funds and other institutional investors.

About DICE Therapeutics (Get a rating)

DICE Therapeutics, Inc, a biopharmaceutical company, constructs various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its DELSCAPE platform is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

See also

Get a Free Copy of Zacks’ Research Report on DICE Therapeutics (DICE)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in DICE Therapeutics right now?

Before you consider DICE Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and DICE Therapeutics wasn’t on the list.

Although DICE Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

About Tina G.

Check Also

Tivity Health (NASDAQ:TVTY) receives new coverage from StockNews.com analysts

StockNews.com investment analysts have started covering stocks of Tivity Health (NASDAQ:TVTY – Get Note) in …